Overview

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Status:
Terminated
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost